Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Changes in peripheral benzodiazepine receptors in patients with bipolar disorder.

Neuropsychiatric disease and treatment

Marazziti D, Dell'Osso B, Baroni S, Masala I, Nasso ED, Giannaccini G, Dell'Osso L.
PMID: 18568060
Neuropsychiatr Dis Treat. 2005 Jun;1(2):151-4. doi: 10.2147/nedt.1.2.151.61046.

Peripheral benzodiazepine (BDZ) receptors were investigated by means of the binding of the specific ligand (3)H-PK 11195 to platelet membranes in patients suffering from bipolar disorder and in healthy controls. The results showed that the density (Bmax) of peripheral...

Cite
Marazziti D, Dell'Osso B, Baroni S, et al. Changes in peripheral benzodiazepine receptors in patients with bipolar disorder. Neuropsychiatr Dis Treat. 2005;1(2):151-4doi: 10.2147/nedt.1.2.151.61046.
Marazziti, D., Dell'Osso, B., Baroni, S., Masala, I., Nasso, E. D., Giannaccini, G., & Dell'Osso, L. (2005). Changes in peripheral benzodiazepine receptors in patients with bipolar disorder. Neuropsychiatric disease and treatment, 1(2), 151-4. https://doi.org/10.2147/nedt.1.2.151.61046
Marazziti, Donatella, et al. "Changes in peripheral benzodiazepine receptors in patients with bipolar disorder." Neuropsychiatric disease and treatment vol. 1,2 (2005): 151-4. doi: https://doi.org/10.2147/nedt.1.2.151.61046
Marazziti D, Dell'Osso B, Baroni S, Masala I, Nasso ED, Giannaccini G, Dell'Osso L. Changes in peripheral benzodiazepine receptors in patients with bipolar disorder. Neuropsychiatr Dis Treat. 2005 Jun;1(2):151-4. doi: 10.2147/nedt.1.2.151.61046. PMID: 18568060; PMCID: PMC2413195.
Copy Download .nbib Format: NLM
The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells.

Biology

Monga S, Weizman A, Gavish M.
PMID: 32938018
Biology (Basel). 2020 Sep 14;9(9). doi: 10.3390/biology9090291.

The impact of ligands of the 18 kDa translocator protein (TSPO) on the release of chemokines is not vastly investigated. In the present study, we assessed the effect of our novel TSPO ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 compared to the...

Cite
Monga S, Weizman A, Gavish M. The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells. Biology (Basel). 2020;9(9)doi: 10.3390/biology9090291.
Monga, S., Weizman, A., & Gavish, M. (2020). The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells. Biology, 9(9), . https://doi.org/10.3390/biology9090291
Monga, Sheelu, et al. "The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells." Biology vol. 9,9 (2020). doi: https://doi.org/10.3390/biology9090291
Monga S, Weizman A, Gavish M. The Efficacy of the Novel TSPO Ligands 2-Cl-MGV-1 and 2,4-Di-Cl-MGV-1 Compared to the Classical TSPO Ligand PK 11195 to Counteract the Release of Chemokines from LPS-Stimulated BV-2 Microglial Cells. Biology (Basel). 2020 Sep 14;9(9). doi: 10.3390/biology9090291. PMID: 32938018; PMCID: PMC7565396.
Copy Download .nbib Format: NLM
Delayed developmental immunotoxicity of prenatal benzodiazepines.

Toxicology in vitro : an international journal published in association with BIBRA

Schlumpf M, Bütikofer EE, Schreiber AA, Parmar R, Ramseier HR, Lichtensteiger W.
PMID: 20693072
Toxicol In Vitro. 1994 Oct;8(5):1061-5. doi: 10.1016/0887-2333(94)90245-3.

Treatment of pregnant rats with low doses of classical benzodiazepines (BDZ, e.g. 1.25 mg diazepam/kg body weight) or a peripheral type BDZ receptor (PBR) agonist between gestational days 14 and 20 has been shown to result in a long-lasting...

Cite
Schlumpf M, Bütikofer EE, Schreiber AA, et al. Delayed developmental immunotoxicity of prenatal benzodiazepines. Toxicol In Vitro. 1994;8(5):1061-5doi: 10.1016/0887-2333(94)90245-3.
Schlumpf, M., Bütikofer, E. E., Schreiber, A. A., Parmar, R., Ramseier, H. R., & Lichtensteiger, W. (1994). Delayed developmental immunotoxicity of prenatal benzodiazepines. Toxicology in vitro : an international journal published in association with BIBRA, 8(5), 1061-5. https://doi.org/10.1016/0887-2333(94)90245-3
Schlumpf, M, et al. "Delayed developmental immunotoxicity of prenatal benzodiazepines." Toxicology in vitro : an international journal published in association with BIBRA vol. 8,5 (1994): 1061-5. doi: https://doi.org/10.1016/0887-2333(94)90245-3
Schlumpf M, Bütikofer EE, Schreiber AA, Parmar R, Ramseier HR, Lichtensteiger W. Delayed developmental immunotoxicity of prenatal benzodiazepines. Toxicol In Vitro. 1994 Oct;8(5):1061-5. doi: 10.1016/0887-2333(94)90245-3. PMID: 20693072.
Copy Download .nbib Format: NLM
"Peripheral" benzodiazepine receptor density is not altered by methylphenidate treatment in children with attention-deficit hyperactivity disorder.

Journal of child and adolescent psychopharmacology

Weizman R, Dar DE, Landa S, Apter A, Gavish M.
PMID: 19630638
J Child Adolesc Psychopharmacol. 1993;3(2):63-9. doi: 10.1089/cap.1993.3.63.

ABSTRACT "Peripheral" benzodiazepine receptors (PBRs) are located in the central nervous system and the periphery, are involved in the release of dopamine, and are sensitive to agents active at the dopaminergic system. Because attention-deficit hyperactivity disorder (ADHD) is related...

Cite
Weizman R, Dar DE, Landa S, et al. "Peripheral" benzodiazepine receptor density is not altered by methylphenidate treatment in children with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 1993;3(2):63-9doi: 10.1089/cap.1993.3.63.
Weizman, R., Dar, D. E., Landa, S., Apter, A., & Gavish, M. (1993). "Peripheral" benzodiazepine receptor density is not altered by methylphenidate treatment in children with attention-deficit hyperactivity disorder. Journal of child and adolescent psychopharmacology, 3(2), 63-9. https://doi.org/10.1089/cap.1993.3.63
Weizman, R, et al. ""Peripheral" benzodiazepine receptor density is not altered by methylphenidate treatment in children with attention-deficit hyperactivity disorder." Journal of child and adolescent psychopharmacology vol. 3,2 (1993): 63-9. doi: https://doi.org/10.1089/cap.1993.3.63
Weizman R, Dar DE, Landa S, Apter A, Gavish M. "Peripheral" benzodiazepine receptor density is not altered by methylphenidate treatment in children with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 1993;3(2):63-9. doi: 10.1089/cap.1993.3.63. PMID: 19630638.
Copy Download .nbib Format: NLM
Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model.

Frontiers in medicine

Sérrière S, Doméné A, Vercouillie J, Mothes C, Bodard S, Rodrigues N, Guilloteau D, Routier S, Page G, Chalon S.
PMID: 26389120
Front Med (Lausanne). 2015 Sep 02;2:61. doi: 10.3389/fmed.2015.00061. eCollection 2015.

The inverse association between nicotine intake and Parkinson's disease (PD) is well established and suggests that this molecule could be neuroprotective through anti-inflammatory action mediated by nicotinic receptors, including the α7-subtype (α7R). The objective of this study was to...

Cite
Sérrière S, Doméné A, Vercouillie J, et al. Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model. Front Med (Lausanne). 2015;2:61doi: 10.3389/fmed.2015.00061.
Sérrière, S., Doméné, A., Vercouillie, J., Mothes, C., Bodard, S., Rodrigues, N., Guilloteau, D., Routier, S., Page, G., & Chalon, S. (2015). Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model. Frontiers in medicine, 261. https://doi.org/10.3389/fmed.2015.00061
Sérrière, Sophie, et al. "Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model." Frontiers in medicine vol. 2 (2015): 61. doi: https://doi.org/10.3389/fmed.2015.00061
Sérrière S, Doméné A, Vercouillie J, Mothes C, Bodard S, Rodrigues N, Guilloteau D, Routier S, Page G, Chalon S. Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model. Front Med (Lausanne). 2015 Sep 02;2:61. doi: 10.3389/fmed.2015.00061. eCollection 2015. PMID: 26389120; PMCID: PMC4556971.
Copy Download .nbib Format: NLM
'Peripheral' benzodiazepine receptor ligands stimulate prolactin release in the rat.

Journal of neuroendocrinology

Calogerot AE, Kamilaris TC, Johnson EO, Gold PW, Chrousos GP.
PMID: 19215414
J Neuroendocrinol. 1990 Oct 01;2(5):745-50. doi: 10.1111/j.1365-2826.1990.tb00473.x.

Abstract High concentrations of 'peripheral' benzodiazepine binding sites have been described in the pituitary gland and in several other endocrine glands, such as the adrenal glands and the testes. The role played by these receptors on the regulation of...

Cite
Calogerot AE, Kamilaris TC, Johnson EO, et al. 'Peripheral' benzodiazepine receptor ligands stimulate prolactin release in the rat. J Neuroendocrinol. 1990;2(5):745-50doi: 10.1111/j.1365-2826.1990.tb00473.x.
Calogerot, A. E., Kamilaris, T. C., Johnson, E. O., Gold, P. W., & Chrousos, G. P. (1990). 'Peripheral' benzodiazepine receptor ligands stimulate prolactin release in the rat. Journal of neuroendocrinology, 2(5), 745-50. https://doi.org/10.1111/j.1365-2826.1990.tb00473.x
Calogerot, A E, et al. "'Peripheral' benzodiazepine receptor ligands stimulate prolactin release in the rat." Journal of neuroendocrinology vol. 2,5 (1990): 745-50. doi: https://doi.org/10.1111/j.1365-2826.1990.tb00473.x
Calogerot AE, Kamilaris TC, Johnson EO, Gold PW, Chrousos GP. 'Peripheral' benzodiazepine receptor ligands stimulate prolactin release in the rat. J Neuroendocrinol. 1990 Oct 01;2(5):745-50. doi: 10.1111/j.1365-2826.1990.tb00473.x. PMID: 19215414.
Copy Download .nbib Format: NLM
TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT.

ACS medicinal chemistry letters

Chen Y, Sajjad M, Wang Y, Batt C, Nabi HA, Pandey RK.
PMID: 24900292
ACS Med Chem Lett. 2010 Nov 23;2(2):136-41. doi: 10.1021/ml100211g. eCollection 2011 Feb 10.

Translocator protein (TSPO) 18 kDa overexpression has been observed in a large variety of human cancers, especially breast cancers. PK 11195, an isoquinoline analogue, is one of the ligands of highest TSPO binding affinity. Due to the long biological...

Cite
Chen Y, Sajjad M, Wang Y, et al. TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT. ACS Med Chem Lett. 2010;2(2):136-41doi: 10.1021/ml100211g.
Chen, Y., Sajjad, M., Wang, Y., Batt, C., Nabi, H. A., & Pandey, R. K. (2011). TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT. ACS medicinal chemistry letters, 2(2), 136-41. https://doi.org/10.1021/ml100211g
Chen, Yihui, et al. "TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT." ACS medicinal chemistry letters vol. 2,2 (2011): 136-41. doi: https://doi.org/10.1021/ml100211g
Chen Y, Sajjad M, Wang Y, Batt C, Nabi HA, Pandey RK. TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT. ACS Med Chem Lett. 2010 Nov 23;2(2):136-41. doi: 10.1021/ml100211g. eCollection 2011 Feb 10. PMID: 24900292; PMCID: PMC4018113.
Copy Download .nbib Format: NLM
Structure-to-function relationships of bacterial translocator protein (TSPO): a focus on Pseudomonas.

Frontiers in microbiology

Leneveu-Jenvrin C, Connil N, Bouffartigues E, Papadopoulos V, Feuilloley MG, Chevalier S.
PMID: 25477872
Front Microbiol. 2014 Nov 19;5:631. doi: 10.3389/fmicb.2014.00631. eCollection 2014.

The translocator protein (TSPO), which was previously designated as the peripheral-type benzodiazepine receptor, is a 3.5 billion year-old evolutionarily conserved protein expressed by most Eukarya, Archae and Bacteria, but its organization and functions differ remarkably. By taking advantage of...

Cite
Leneveu-Jenvrin C, Connil N, Bouffartigues E, et al. Structure-to-function relationships of bacterial translocator protein (TSPO): a focus on Pseudomonas. Front Microbiol. 2014;5:631doi: 10.3389/fmicb.2014.00631.
Leneveu-Jenvrin, C., Connil, N., Bouffartigues, E., Papadopoulos, V., Feuilloley, M. G., & Chevalier, S. (2014). Structure-to-function relationships of bacterial translocator protein (TSPO): a focus on Pseudomonas. Frontiers in microbiology, 5631. https://doi.org/10.3389/fmicb.2014.00631
Leneveu-Jenvrin, Charlène, et al. "Structure-to-function relationships of bacterial translocator protein (TSPO): a focus on Pseudomonas." Frontiers in microbiology vol. 5 (2014): 631. doi: https://doi.org/10.3389/fmicb.2014.00631
Leneveu-Jenvrin C, Connil N, Bouffartigues E, Papadopoulos V, Feuilloley MG, Chevalier S. Structure-to-function relationships of bacterial translocator protein (TSPO): a focus on Pseudomonas. Front Microbiol. 2014 Nov 19;5:631. doi: 10.3389/fmicb.2014.00631. eCollection 2014. PMID: 25477872; PMCID: PMC4237140.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries